Tyra Biosciences announced a $400 million underwritten offering of common stock and pre-funded warrants priced at about $22 per share. The proceeds will support development of their lead drug candidate dabogratinib for cancers and achondroplasia, as well as other preclinical programs and general corporate purposes. The offering is expected to close on September 15, 2026, with participation from major institutional investors. This capital raise aims to advance Tyra's precision medicine pipeline targeting FGFR biology in oncology and genetic conditions.
FREELANDER participated in the 2026 Chery International User Summit in Wuhu, China, showcasing the international variant of its FREELANDER 8 model through a day-and-night program on October 19. The day featured the first international test drive on c...
Disc Medicine announced a webcast on October 19, 2026, to discuss topline results from its APOLLO Phase 3 trial of bitopertin, an investigational oral drug for erythropoietic protoporphyria (EPP). Bitopertin targets glycine transporter 1 to modulate ...
Ethena (ENA) saw a notable price increase of 9.15% over four hours, reaching $0.1921 on the Binance spot ENA/USDT pair as of October 18. Despite a smaller 24-hour gain of 2.07%, the short-term surge highlights increased trading activity. During the s...
An unidentified large trader's short position on Ether (ETH) valued at $26.64 million faced partial liquidation after the ETH price rebounded to $2,409. The short was initially opened at $2,366 involving 13,830 ETH worth $32.72 million. During the pr...
A short position on Ether (ETH) involving 2,765 ETH, valued at $6.66 million, was partially liquidated on Sunday as the price of ETH rose to $2,409. The short had opened at a price of $2,366 with a total value of $32.72 million. By the evening, the p...
